Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. - Concepedia

Concepedia

Publication | Closed Access

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

69

Citations

0

References

1997

Year

Gordon Rustin, Ann E. Nelstrop, Michael Crawford, JA Ledermann, H Lambert, Rober L. Coleman, Joseph J. Johnson, H Evans, Sherry‐Ann Brown, Wolfgang Oster

Journal of Clinical Oncology

Abstract

Oral altretamine is a useful agent in patients-who relapse after previously responsive ovarian cancer. Response evaluation by a strict CA125 definition gave a similar estimate of the efficacy of altretamine as EORTC criteria.